Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma

This study is testing whether combining an oncolytic virus (a virus engineered to attack cancer cells) with an immune checkpoint drug (PD-1 inhibitor) can help patients with advanced malignant pleural mesothelioma — a rare cancer of the lung lining — whose cancer has stopped responding to immunotherapy. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with advanced mesothelioma that has failed immunotherapy - You have at least one tumor lesion large enough to inject - You are in reasonably good functional health (ECOG 0–2) **You may NOT be eligible if...** - You have uncontrollable medical problems such as severe heart, lung, or neurological disease - You have known contraindications to the study drugs (the oncolytic virus or PD-1 inhibitor) - Your doctor does not expect you to be available for regular follow-up visits Talk to your doctor to see if this trial is right for you.